The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
Movement Disorders Clinical Practice · 2025-07 · 12 (7) · 904-916
DOI: 10.1002/mdc3.70029 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 13.03.2025. Verfasst von Elisa Menozzi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK. Hauptthemen laut MEDLINE: Parkinson Disease, Gastrointestinal Microbiome, Brain, Brain-Gut Axis. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aligning Science Across Parkinson's, EU Joint Programme - Neurodegenerative Disease Research.
Abstract (Originalsprache)
Background
The gut‐brain axis, i.e. the bidirectional communication system between the gut and the brain, has become of central importance in Parkinson disease (PD) research over the past 20 years.
Aims
We aimed to describe the milestones of the gut‐brain axis research in PD and the development of theories proposing the involvement of the gastrointestinal tract in PD pathogenesis.
Methods
We searched PubMed using the terms ‘gut‐brain axis’ AND ‘Parkinson disease’, and selected relevant articles to provide the foundation for reconstructing an historical overview of the gut‐brain axis research in PD.
Results
Mounting evidence from preclinical, clinical and post‐mortem studies suggests that a subgroup of PD patients present with a range of prodromal symptoms (e.g., autonomic dysfunction, rapid eye movement sleep behaviour disorder) which reflect initial accumulation and later spread of pathological α‐synuclein rostrally from the gastrointestinal tract (“body‐first” PD). Through neural connections along the gut‐brain axis, pathological α‐synuclein may spread to the brain, producing clinically manifest disease. Recently, two mechanisms involving the gut‐brain axis have attracted increasing attention for their role in PD pathogenesis and progression, namely the perturbation of the composition of the microorganisms living in the gut (the gut microbiome), and the dysfunction of enteroendocrine cells.
Conclusion
Treatments targeting the gut‐brain axis, especially the gut microbiome and the enteroendocrine cells pathway, could potentially slow disease progression or even prevent disease onset. Among these, pre/probiotics, faecal microbiota transplantation, and glucagon‐like peptide‐1 receptor agonists, have entered advanced stages of clinical trials in humans and shown potential symptomatic and disease‐modifying effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
- Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, Maryland, USA.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Nuclear Medicine and PET, Aarhus University Hospital, Aarhus, Denmark.
ORCID-Profile: Elisa Menozzi
Förderung
- Aligning Science Across Parkinson's
- EU Joint Programme - Neurodegenerative Disease Research
Zitieren
APA
Menozzi, E., Schapira, A. H. V., & Borghammer, P. (2025). The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications. Movement Disorders Clinical Practice, 12(7), 904-916. https://doi.org/10.1002/mdc3.70029
Vancouver
Menozzi E, Schapira AHV, Borghammer P. The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications. Movement Disorders Clinical Practice. 2025;12(7):904-916. doi:10.1002/mdc3.70029
BibTeX
@article{Menozzi2025,
author = {Menozzi, Elisa and Schapira, Anthony H V and Borghammer, Per},
title = {The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications},
journal = {Movement Disorders Clinical Practice},
year = {2025},
volume = {12},
number = {7},
pages = {904--916},
doi = {10.1002/mdc3.70029}
}
EUVIMED